Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.24.1.1.u2
Revenues from Contracts and Significant Customers (Tables)
3 Months Ended
Mar. 31, 2024
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

Three Months Ended March 31, 

​

    

2024

    

2023

Revenue

​

​

​

​

​

​

Qbrexza

​

$

5,017

​

$

4,094

Accutane

​

​

5,819

​

​

4,648

Amzeeq

​

​

755

​

​

1,193

Zilxi

​

​

273

​

​

314

Other / legacy product revenue

​

​

1,166

​

​

1,916

Collaboration revenue

​

​

—

​

​

181

Revenue – related party

​

 

—

​

 

35

Other revenue

​

​

—

​

 

48

Total net revenue

​

$

13,030

​

$

12,429